PYC Therapeutics (ASX:PYC) EBIT: A$-48.21 Mil (TTM As of Dec. 2025)

What is PYC Therapeutics EBIT?

PYC Therapeutics ASX:PYC 35 EBIT is A$-48.21 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

PYC Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-23.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-48.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PYC Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 was -278.14%. PYC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -355.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PYC Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3.47%.

PYC Therapeutics (ASX:PYC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PYC Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-66.998 * ( 1 - 0% )	/	( (19.294	+	28.882)	/ 2 )
=	-66.998	/	24.088
=	-278.14 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	183.279	-	10.935	-	( 153.05	-	max(0, 12.317	-	177.526	+	153.05	))
=	19.294

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	159.13	-	9.556	-	( 120.692	-	max(0, 11.011	-	153.739	+	120.692	))
=	28.882

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

PYC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-46.192	/	( ( (1.903 + max(-11.51, 0))	+	(1.642 + max(22.426, 0)) )	/	2 )
=	-46.192	/	( ( 1.903	+	24.068 )	/	2 )
=	-46.192	/	12.9855
=	-355.72 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.40799999999999)	-	(10.935	+	0	+	0.983)
=	-11.51

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(32.586	+	0	+	0.46100000000001)	-	(9.556	+	0	+	1.065)
=	22.426

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PYC Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-48.209	/	1389.968
	=	-3.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics EBIT Related Terms

PYC Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's EBIT can be seen below:

PYC Therapeutics EBIT Chart

PYC Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBIT

Get a 7-Day Free Trial

-18.59

-14.26

-23.33

-38.06

-50.95

PYC Therapeutics Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-15.22	-22.84	-25.84	-25.11	-23.10

ASX:PYC vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, PYC Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's EV-to-EBIT falls into.

Save Embed

35GF Score

PYC Therapeutics Ltd ASX:PYC

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PYC Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-48.21 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of A$-48.21 Mil mean?

PYC Therapeutics (ASX:PYC) has a EBIT of A$-48.21 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PYC Therapeutics.

Is PYC Therapeutics' EBIT too high?

PYC Therapeutics' current EBIT is A$-48.21 Mil. Overall, PYC Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does PYC Therapeutics' EBIT compare to VRTX and REGN?

PYC Therapeutics' EBIT of A$-48.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PYC Therapeutics. PYC Therapeutics's current EBIT is A$-48.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PYC Therapeutics stock overvalued right now?

PYC Therapeutics (ASX:PYC) has a current EBIT of A$-48.21 Mil. The current EBIT is A$-48.21 Mil. PYC Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current EBIT is A$-48.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:CU6 ASX:NEU ASX:RAC ASX:CUV ASX:TTX ASX:SPL ASX:OCC ASX:RCE ASX:ACW ASX:NYR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges PYCXF:USA

Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009

Website https://www.pyctx.com

PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

35GF Score

Get the complete analysis for ASX:PYC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54

Price

View ASX:PYC Analysis

See EBIT data for all stocks →